NCT02508896View on ClinicalTrials.gov

Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

August 31, 2017

Conditions
Hypercholesterolemia
Interventions
BIOLOGICAL

AFFITOPE® AT04A+adjuvant

subcutaneous injection

BIOLOGICAL

AFFITOPE® AT06A+adjuvant

subcutaneous injection

BIOLOGICAL

Adjuvant without active component

subcutaneous injection

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors
collaborator

Medical University of Vienna

OTHER

lead

Affiris AG

INDUSTRY

NCT02508896 - Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects | Biotech Hunter | Biotech Hunter